Skip to main content
. 2021 Aug 19;36(2):507–515. doi: 10.1038/s41375-021-01382-3

Fig. 5. Myeloid CH predicts adverse outcomes in CKD.

Fig. 5

The forest plots show data stratified according to eGFR.cys as healthy (≥90), mild CKD (≥60 to <90) and moderate CKD (≥15 to <60). The risk of adverse outcomes was predicted by myeloid CH in all groups but was particularly marked (HR = 1.6, P = 0.002) for participants with moderate CKD.